(0.08%) 5 521.50 points
(0.13%) 39 894 points
(0.18%) 19 787 points
(-0.04%) $81.60
(0.68%) $2.83
(-0.23%) $2 338.90
(0.05%) $29.54
(0.47%) $1 006.50
(0.06%) $0.932
(-0.10%) $10.52
(0.02%) $0.788
(-0.84%) $87.26
-35.81% $ 0.0398
Live Chart Being Loaded With Signals
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV)...
Stats | |
---|---|
Dzisiejszy wolumen | 928 |
Średni wolumen | 0 |
Kapitalizacja rynkowa | 20.86M |
EPS | $-0.540 ( Q1 | 2024-05-20 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0.140 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-07 | Sullivan Eddie Joe | Buy | 1 740 | Common Stock |
2023-11-30 | King Michael | Buy | 5 000 | Common Stock |
2023-11-29 | Reich Samuel J | Buy | 11 000 | Common Stock |
2023-11-24 | Sessa Capital (master), L.p. | Buy | 4 584 571 | Common Stock |
2023-11-24 | Sessa Capital (master), L.p. | Buy | 28 380 | Series A-2 Convertible Preferred Stock |
INSIDER POWER |
---|
67.59 |
Last 48 transactions |
Buy: 15 469 696 | Sell: 3 137 380 |
SAB Biotherapeutics, Inc. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
SAB Biotherapeutics, Inc. Finanse
Annual | 2023 |
Przychody: | $2.24M |
Zysk brutto: | $-1.51M (-67.28 %) |
EPS: | $-7.64 |
FY | 2023 |
Przychody: | $2.24M |
Zysk brutto: | $-1.51M (-67.28 %) |
EPS: | $-7.64 |
FY | 2022 |
Przychody: | $23.90M |
Zysk brutto: | $20.61M (86.23 %) |
EPS: | $-4.31 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej